Evommune, Inc. (NYSE:EVMN – Get Free Report) CEO Luis Pena sold 7,438 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $22.71, for a total transaction of $168,916.98. Following the sale, the chief executive officer owned 630,458 shares of the company’s stock, valued at approximately $14,317,701.18. This represents a 1.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Evommune Stock Performance
Shares of EVMN opened at $24.93 on Friday. The firm has a market cap of $898.16 million and a P/E ratio of -2.62. Evommune, Inc. has a 52 week low of $13.89 and a 52 week high of $33.20. The firm’s 50-day simple moving average is $22.98 and its 200 day simple moving average is $22.31.
Evommune (NYSE:EVMN – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.19. As a group, equities analysts forecast that Evommune, Inc. will post -2.85 earnings per share for the current year.
Institutional Inflows and Outflows
Analyst Ratings Changes
EVMN has been the subject of several recent research reports. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Evommune in a research note on Tuesday, May 26th. Clear Str upgraded Evommune to a “strong-buy” rating in a research report on Tuesday, March 17th. Stifel Nicolaus assumed coverage on Evommune in a report on Friday, May 1st. They set a “buy” rating and a $54.00 target price for the company. Royal Bank Of Canada restated an “outperform” rating and issued a $48.00 price target on shares of Evommune in a research note on Friday, April 10th. Finally, Wall Street Zen lowered shares of Evommune from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Three research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $49.25.
Get Our Latest Stock Analysis on EVMN
About Evommune
Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.
Featured Articles
- Five stocks we like better than Evommune
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Receive News & Ratings for Evommune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evommune and related companies with MarketBeat.com's FREE daily email newsletter.
